LifeSpan BioSciences provides high-quality antibodies, proteins, biochemicals, ELISA and Assay kits, immunohistochemistry data and services to researchers worldwide.
LSBio has a catalog of 550,000 monoclonal and polyclonal antibodies to 20,000 targets. Antibodies are available for most species and all major research applications, such as immunoblotting, IHC, immunofluorescence, and fluorescence-activated cell sorting. Through extensive ongoing in-house testing, more than 14,000 of these antibodies have also been identified as exceptional IHC reagents, and given the IHC-plus™ brand.
LSBio also offers 30,000 high-quality immunoassays, including Sandwich ELISA (enzyme-linked immunosorbent assay) kits, Competitive EIA (Enzyme Immunoassay) kits, as well as cell-based and DNA-binding kits.
LSBio also offers 45,000 native protein extracts as well as engineered recombinant proteins in the form of cell lysates or highly-purified reagents.
More recently LSBio has released their growing collections of Assay Kits and BioChemicals intended to complement their other product lines for the research community.
IHC-plus™ Antibodies …because seeing is believing!
LSBio’s IHC-plus™ antibodies have been tested and identified as being optimal for use in immunohistochemistry (IHC) against formalin-fixed paraffin-embedded (FFPE) human tissues under LSBio’s standardized IHC-plus™ immunohistochemistry protocol.
Each antibody is tested at multiple concentrations on more than 20 normal human tissue types, and when appropriate, multiple normal brain regions and/or cancer types. LSBio’s IHC protocol has been developed over the past 15 years as the most optimal method of immunolabeling FFPE tissues, the most common fixation method used by pathology labs worldwide. A LifeSpan pathologist, with extensive experience evaluating IHC, analyzes the localization profile of each antibody, identifying positive and negative cell types, signal strength, subcellular and extracellular staining, and staining artifacts. This information is then compared with all published expression and localization data available for the protein. This enables LSBio to evaluate how each antibody behaves in IHC, including its specificity to the target protein, its sensitivity of detection, and any non-specific staining characteristics that it may display. In order to be selected as an IHC-plus™ brand antibody, antibodies must have a close correlation to the published literature, be high affinity, display minimal staining artifacts, and have a high signal-to-noise ratio, such that its specific staining is considerably higher than its level of nonspecific background staining. Learn more about LSBio’s Immunohistochemistry (IHC) Validation.
View all IHC-plus™ antibodies HERE.